<DOC>
	<DOC>NCT01388491</DOC>
	<brief_summary>This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.</brief_summary>
	<brief_title>A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal, nonpregnant, nonlactating women age 1840 years old Body Mass Index (BMI) ≥18 kg/m² and &lt;30 kg/m² Regular spontaneous menstrual cycle Others as dictated by FDAapproved protocol Any condition which contraindicates the use of combination oral contraceptives Any history of, or active, deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease within one year of screening Thrombophlebitis or thromboembolic disorders; known or suspected clotting disorders; thrombogenetic valvulopathies or rhythm disorders Others as dictated by FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Blood Coagulation</keyword>
</DOC>